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1. INTRODUCTION {#jmv25502-sec-0050}
===============

Acute lower respiratory tract infection (ALRTI) is one of the main causes of hospitalization, morbidity, and mortality in children.[1](#jmv25502-bib-0001){ref-type="ref"}, [2](#jmv25502-bib-0002){ref-type="ref"} Severe ALRTI (SALRTI) accounts for most hospital admissions in young children worldwide, with an estimated 11.9 million (95% confidence interval 10.3‐13.9 million) cases, whereas very SALRTI accounts for an estimated 3 million (2.1‐4.2 million) cases. Concomitantly, such infections resulted in about 2.8 million deaths worldwide in 2010.[3](#jmv25502-bib-0003){ref-type="ref"}, [4](#jmv25502-bib-0004){ref-type="ref"}, [5](#jmv25502-bib-0005){ref-type="ref"} Children who suffer from SALRTI require intensive medical management, imposing a great societal burden, particularly in India, China, Pakistan, Bangladesh, Indonesia, and Nigeria.[6](#jmv25502-bib-0006){ref-type="ref"}, [7](#jmv25502-bib-0007){ref-type="ref"}

The etiological factor in young children is a viral infection or a combination of viral and bacterial infection, which is apparently different from that of ALRTI caused by bacteria in adults. Therefore, the lack of effective diagnostic methods for the identification of the etiological factor is the major reason why more than 50% of ALRTIs were treated unnecessarily and inappropriately with antibiotics, even in the case of viral infection.[8](#jmv25502-bib-0008){ref-type="ref"} This often leads to serious consequences such as a high rate of antibiotic resistance,[9](#jmv25502-bib-0009){ref-type="ref"} especially in virus‐infected children with SALRTI. Therefore, a better understanding of the epidemiology of viral respiratory tract infections in critically ill children is essential for the development of a novel strategy for SALRTI prevention, control, and treatment.

Although several studies have been conducted to investigate the prevalence of viral ALRTIs in Northern China, particularly in Beijing and Shanghai, the viral pathogens that cause ALRTI, especially those causing SALRTI, in Southern China have not yet been established. As a representative city in Southern China, Guangzhou is a first‐tier city with a high population density and disease mobility. To gain insight into respiratory viruses in children with SALRTI for future diagnosis and antiviral treatment, a comprehensive evaluation of viral etiology and clinical characterization was conducted among hospitalized children with SALRTI admitted to the pediatric intensive care unit (PICU) of the Third Affiliated Hospital of Sun Yat‐Sen University between May 2015 and April 2018.

2. MATERIALS AND METHODS {#jmv25502-sec-0060}
========================

2.1. Ethics statement {#jmv25502-sec-0070}
---------------------

This study was conducted in compliance with the protocol approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat‐Sen University. Written informed consent was obtained from the patients' guardians before enrollment.

2.2. Participants and clinical definitions {#jmv25502-sec-0080}
------------------------------------------

The study participants consisted of children admitted to the PICU of the Third Affiliated Hospital of Sun Yat‐Sen University between May 2015 and April 2018. SALRTI was diagnosed according to the clinical guidelines recommended by the World Health Organization.[10](#jmv25502-bib-0010){ref-type="ref"}, [11](#jmv25502-bib-0011){ref-type="ref"} The eligibility and classification of the clinical syndromes of SALRTI were determined from each patient\'s original medical history and physical examination records. The inclusion criteria were as follows: (children \> 5 years of age) sudden onset of fever \> 38°C, cough or sore throat, shortness of breath or difficulty breathing, and requiring hospitalization; (children \< 5 years of age) meeting either (1) the Integrated Management of Childhood Illness (IMCI) criteria for pneumonia (any child 2 months to 5 years of age with cough or difficulty breathing and breathing faster than 60 breaths/min \[infants \< 2 months\], breathing faster than 50 breaths/min (2‐12 months), or breathing faster than 40 breaths/min \[1‐5 years\]) or (2) the IMCI criteria for severe pneumonia (any child 2 months to 5 years of age with cough or difficulty breathing and any of the following general danger signs: unable to drink or breastfeed, vomits everything, convulsions, lethargic or unconscious, chest indrawing, or stridor in a calm child) and (3) requiring hospital admission. Nasopharyngeal aspirate (NPA) or induced sputum (IS) was collected from the patients at the first day of admission and transferred into the virus transport medium. Demographic information and medical test results were obtained using standardized forms.

2.3. Multiplex polymerase chain reaction tests {#jmv25502-sec-0090}
----------------------------------------------

Viral nucleic acids were simultaneously extracted from 200 μL of NPA specimens or IS using QIAamp MinElute Virus Spin Kit (Qiagen, Hilden, Germany) following the manufacturer\'s instructions. Reverse transcription of virus RNA was performed using Thermo Fisher Scientific Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA), and the incubation procedure was performed as follows: 25℃ for 5 minutes, 42℃ for 60 minutes, and 70℃ for 5 minutes. cDNA was used for virus detection immediately or stored at −20℃ until further use. Each sample was tested simultaneously for the following eight categories of respiratory viruses: influenza virus (IFV) (five type A subtypes, including H1N1, H3N2, pandemic H1N1 2009, H5N1, and H7N9, as well as type B virus), parainfluenza types 1 to 4 (PIV1, PIV2, PIV3, and PIV4), respiratory syncytial virus (RSV) type A and B, human metapneumovirus (HMPV), six strains of human coronavirus (HCoV, including HCoV‐229E, OC43, NL63, HKU1, SARS, and MERS), adenovirus (ADV), human rhinovirus (HRV), and human bocavirus (HBoV). These viruses were detected using either real‐time polymerase chain reaction (PCR) or reverse transcription‐PCR. The procedure was described previously,[12](#jmv25502-bib-0012){ref-type="ref"}, [13](#jmv25502-bib-0013){ref-type="ref"}, [14](#jmv25502-bib-0014){ref-type="ref"}, [15](#jmv25502-bib-0015){ref-type="ref"}, [16](#jmv25502-bib-0016){ref-type="ref"} with specific primers and probes listed in Table [1](#jmv25502-tbl-0001){ref-type="table"}.

###### 

The Primers and probes used for respiratory viruses screening

  Virus                    Primer/probe                                      Sequence (5′‐3′)                 Target gene    PCR product (bp)
  ------------------------ ------------------------------------------------- -------------------------------- -------------- ------------------
  IFV‐A                    IFV A‐F                                           GACCRATCCTGTCACCTCTGAC           M              82
  IFV A‐R                  AGGGCATTYTGGACAAAKCGTCTA                                                                          
  IFV A‐Probe              FAM‐TGCAGTCCTCGCTCACTGGGCACG‐BHQ1                                                                 
  Seasonal H1N1‐H1‐F       CGAAATATTCCCCAAAGARAGCT                           HA                               76             
  Seasonal H1N1‐H1‐R       CCCRTTATGGGAGCATGATG                                                                              
  Seasonal H1N1‐H1‐Probe   FAM‐TGGCCCAACCACACCGTAACCG‐BHQ1                                                                   
  Seasonal H1N1‐N1‐F       GATGGGCTATATACACAAAAGACAACA                       NA                               257            
  Seasonal H1N1‐N1‐R       TGCTGACCATGCAACTGATT                                                                              
  Seasonal H1N1‐N1‐Probe   FAM‐TATAGGGCCTTAATGAGCTGTCCTCTAGG‐BHQ1                                                            
  Seasonal H3N2‐H3‐F       ACCAGAGAAACAAACTAGAGGCATATT                       HA                               120            
  Seasonal H3N2‐H3‐R       TGTCCTGTGCCCTCAGAATTT                                                                             
  Seasonal H3N2‐H3‐Probe   FAM‐CGGTTGGTACGGTTTCAGGCA‐BHQ1                                                                    
  Seasonal H3N2‐N2‐F       TGTATCTGACCAACACCACCATAGA                         NA                               77             
  Seasonal H3N2‐N2‐R       TTGCGGCTTTGACCAATTTC                                                                              
  Seasonal H3N2‐N2‐Probe   FAM‐AAGGAAATATGCCCCAAACTAGCAGAATAC‐BHQ1                                                           
  Pandemic H1N1‐H1‐F       TTATCATTTCAGATACACCAGT                            HA                               179            
  Pandemic H1N1‐H1‐R       AATAGACGGGACATTCCT                                                                                
  Pandemic H1N1‐H1‐Probe   FAM‐CCACGATTGCAATACAACT‐BHQ1                                                                      
  Pandemic H1N1‐N1‐F       CAGAGGGCGACCCAAAGAGA                              NA                               93             
  Pandemic H1N1‐N1‐R       GGCCAAGACCAACCCACA                                                                                
  Pandemic H1N1‐N1‐Probe   FAM‐CACAATCTGGACTAGCGGGAGCAGCAT‐BHQ1                                                              
  H5N1‐H5‐F                GGAACTTACCAAATACTGTCAATTTATTCA                    HA                               84             
  H5N1‐H5‐R                CCATAAAGATAGACCAGCTACCATGA                                                                        
  H5N1‐H5‐Probe            FAM‐TTGCCAGTGCTAGGGAACTCGCCAC‐BHQ1                                                                
  H7N9‐H7‐F                AGAGTCATTRCARAATAGAATACAGAT                       HA                               159            
  H7N9‐ H7‐R               CACYGCATGTTTCCATTCTT                                                                              
  H7N9‐ H7‐Probe           FAM‐AAACATGATGCCCCGAAGCTAAAC‐BHQ1                                                                 
  H7N9‐N9‐F                GTTCTATGCTCTCAGCCAAGG                             NA                               153            
  H7N9‐N9‐R                CTTGACCACCCAATGCATTC                                                                              
  H7N9‐N9‐Probe            FAM‐TAAGCTRGCCACTATCATCACCRCC‐BHQ1                                                                
  IFV‐B                    IFV B‐F                                           TGCCTACCTGCTTTMMYTRACA           M              75
  IFV B‐R                  CCRAACCAACARTGTAATTTTTCTG                                                                         
  IFV B‐Probe              FAM‐TGCTTTGCCTTCTCCA‐BHQ1                                                                         
  RSV‐A                    RSV A‐F                                           GCTCTTAGCAAAGTCAAGTTGAATGA       N              82
  RSV A‐R                  TGCTCCGTTGGATGGTGTATT                                                                             
  RSV A‐Probe              FAM‐ACACTCAACAAAGATCAACTTCTGTCATCCAGC‐BHQ1                                                        
  RSV‐B                    RSV B‐F                                           GATGGCTCTTAGCAAAGTCAAGTTAA       N              104
  RSV B‐R                  TGTCAATATTATCTCCTGTACTACGTTGAA                                                                    
  RSV B‐Probe              FAM‐TGATACATTAAATAAGGATCAGCTGCTGTCATCCA‐BHQ1                                                      
  PIV1                     PIV1‐F                                            ATCTCATTATTACCYGGACCAAGTCTACT    HN             128
  PIV1‐R                   CATCCTTGAGTGATTAAGTTTGATGAATA                                                                     
  PIV1‐Probe               FAM‐AGGATGTGTTAGAYTACCTTCATTATCAATTGGTGATG‐BHQ1                                                   
  PIV2                     PIV2‐F                                            CTGCAGCTATGAGTAATC               NP             119
  PIV2‐R                   TGATCGAGCATCTGGAAT                                                                                
  PIV2‐Probe               FAM‐AGCCATGCATTCACCAGAAGCCAGC‐BHQ1                                                                
  PIV3                     PIV3‐F                                            ACTCTATCYACTCTCAGACC             NP             106
  PIV3‐R                   TGGGATCTCTGAGGATAC                                                                                
  PIV3‐Probe               FAM‐AAGGGACCACGCGCTCCTTTCATC‐BHQ1                                                                 
  PIV4                     PIV4‐F                                            GATCCACAGCAAAGATTCAC             NP             113
  PIV4‐R                   GCCTGTAAGGAAAGCAGAGA                                                                              
  PIV4‐Probe               FAM‐TATCATCATCTGCCAAATCGGCAA‐BHQ1                                                                 
  HMPV                     HMPV‐F                                            CATAYAARCATGCTATATTAAAAGAGTCTC   NP             162
  HMPV‐R                   CCTATYTCTGCAGCATATTTGTAATCAG                                                                      
  HMPV‐Probe               FAM‐TGYAATGATGARGGTGTCACTGCRGTTG‐BHQ1                                                             
  HCoV‐229E                229E‐F                                            CAGTCAAATGGGCTGATGCA             NP             76
  229E‐R                   AAAGGGCTATAAAGAGAATAAGGTATTCT                                                                     
  229E‐Probe               FAM‐CCCTGACGACCACGTTGTGGTTCA‐BHQ1                                                                 
  HCoV‐NL63                NL63‐F                                            GACCAAAGCACTGAATAACATTTTCC       NP             109
  NL63‐R                   ACCTAATAAGCCTCTTTCTCAACCC                                                                         
  NL63‐Probe               FAM‐AACACGCTTCCAACGAGGTTTCTTCAACTGAG‐BHQ1                                                         
  HCoV‐OC43                OC43‐F                                            GAAGGTCTGCTCCTAATTCCAGAT         NP             206
  OC43‐R                   TTTGGCAGTATGCTTAGTTACTT                                                                           
  OC43‐Prob                FAM‐TGCCAAGTTTTGCCAGAACAAGACTAGC‐BHQ1                                                             
  HCoV‐HKU1                HKU1‐F                                            CCTTGCGAATGAATGTGCT              Replicase 1b   94
  HKU1‐R                   TTGCATCACCACTGCTAGTACCAC                                                                          
  HKU1‐Probe               FAM‐TGTGTGGCGGTTGCTATTATGTTAAGCCTG‐BHQ1                                                           
  HCoV‐MERS                BetaCoV_NF1083                                    CAAAACCTTCCCTAAGAAGGAAAAG        NP             83
  BetaCoV_NF1165           GCTCCTTTGGAGGTTCAGACAT                                                                            
  BetaCoV_NPr1110          FAM‐ACAAAAGGCACCAAAAGAAGAATCAACAGACC‐BHQ1                                                         
  HCoV‐SARS                SARS‐F                                            GCATAYAAAACATTCCCACCAA           NP             120
  SARS‐R                   AGCCGCAGGAAGAAGAGTCA                                                                              
  SARS‐Probe               FAM‐ACTGATGAAGCTCAGCCTTTRCCGC‐BHQ1                                                                
  HRV                      HRV‐F                                             TGGACAGGGTGTGAAGAGC              5′UTR          144
  HRV‐R                    CAAAGTAGTCGGTCCCATCC                                                                              
  HRV‐Probe                FAM‐TCCTCCGGCCCCTGAATG‐BHQ1                                                                       
  ADV                      ADV‐F                                             GCCACGGTGGGGTTTCTAAACTT          Hexon          132
  ADV‐R                    GCCCCAGTGGTCTTACATGCACATC                                                                         
  ADV‐Probe                FAM‐TGCACCAGACCCGGGCTCAGGTACTCCGA‐BHQ1                                                            
  HBoV                     HBoV‐F                                            TGCAGACAACGCYTAGTTGTTT           NS1            88
  HBoV‐R                   CTGTCCCGCCCAAGATACA                                                                               
  HBoV‐Probe               FAM‐CCAGGATTGGGTGGAACCTGCAAA‐BHQ1                                                                 

*Note*: K = G or T; M = A or C; R = A or G; S = G or C; Y = C or T; W = A or T; D = A or G or T; N = A or C or G or T.

Abbreviations: ADV, adenovirus; HBoV, human bocavirus; HCoV, human coronavirus; HMPV, human metapneumovirus; HRV, human rhinovirus; IFV, influenza virus; PIV, parainfluenza virus; RSV, respiratory syncytial virus.
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2.4. Statistical analysis {#jmv25502-sec-0100}
-------------------------

Data obtained were entered into a database prepared with Microsoft Excel (Microsoft, Washington, DC). The distribution of viral findings was analyzed in terms of the following factors: (1) sex, (2) patient age, (3) seasonality of sampling, and (4) clinical characteristics of respiratory viruses. the *χ* ^2^ test and Fisher\'s exact test, performed with SPSS (v18.0, SPSS, Chicago, IL), were used for comparisons between groups when applicable. All tests were performed with a type I error of 0.05.

3. RESULTS {#jmv25502-sec-0110}
==========

3.1. Characteristics of patients with SALRTI in the PICU {#jmv25502-sec-0120}
--------------------------------------------------------

During the investigation, 659 samples from patients with SALRTI were included in the analysis. In accordance with the study definition, repeated samples, defined as samples obtained within 30 days from the same area of the respiratory tract of a given patient, were excluded. Among patients with SALRTI, 82.7% were children under 5 years, with a median age of 1.86 years (interquartile range, 0.62‐4.43 years). In addition, 417 (63.3%) patients were male. Coughing and body temperature over 38°C were the most common symptoms (95.6% and 94.4%, respectively). All patients with SALRTI admitted to the PICU underwent a chest X‐ray examination; 507 (76.9%) patients were found to have radiographic evidence of pneumonia (Table [2](#jmv25502-tbl-0002){ref-type="table"}).

###### 

Characteristics of hospitalized patients with SALRTI

  Characteristics                             All SALRTI (%)[^a^](#jmv25502-tbl2-note-0002){ref-type="fn"} (n = 659)   Any viral etiology (%)[^a^](#jmv25502-tbl2-note-0002){ref-type="fn"} (n = 326)   Negative (%)[^a^](#jmv25502-tbl2-note-0002){ref-type="fn"} (n = 333)   *P* value
  ------------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------------- ---------------------------------------------------------------------- -----------
  Gender group                                                                                                                                                                                                                                                                 
  Male sex                                    417 (63.3)                                                               202 (62.0)                                                                       215 (64.6)                                                             0.489
  Female sex                                  242 (36.7)                                                               124 (38.0)                                                                       118 (35.4)                                                             
  Age group                                                                                                                                                                                                                                                                    
  2 mo‐1 y                                    240 (36.4)                                                               133 (40.8)                                                                       107 (32.1)                                                             0.006
  1‐3 y                                       160 (24.3)                                                               87 (26.7)                                                                        73 (21.9)                                                              
  3‐5 y                                       145 (22.0)                                                               66 (20.2)                                                                        79 (23.7)                                                              
  5‐10 y                                      70 (10.6)                                                                27 (8.28)                                                                        43 (12.9)                                                              
  10‐14 y                                     44 (6.7)                                                                 13 (4.0)                                                                         31 (9.3)                                                               
  Clinical history and physical examination                                                                                                                                                                                                                                    
  *T *≥ 38.0°C                                622 (94.4)                                                               303 (92.9)                                                                       319 (95.8)                                                             0.112
  Cough                                       630 (95.6)                                                               310 (95.1)                                                                       320 (96.1)                                                             0.530
  Runny nose                                  165 (25.0)                                                               102 (31.3)                                                                       63 (18.9)                                                              \<0.001
  Sore throat                                 46 (7.0)                                                                 28 (8.6)                                                                         18 (5.4)                                                               0.109
  Sputum production                           404 (61.3)                                                               220 (67.5)                                                                       184 (55.3)                                                             0.001
  Tachypnea                                   262 (39.8)                                                               158 (48.5)                                                                       104 (31.2)                                                             \<0.001
  Difficulty breathing                        411 (62.4)                                                               234 (71.8)                                                                       177 (53.2)                                                             \<0.001
  Wheezing                                    207 (31.4)                                                               148 (45.4)                                                                       59 (17.7)                                                              \<0.001
  Radiographic evidence of pneumonia          507 (76.9)                                                               252 (77.3)                                                                       255 (76.6)                                                             0.825
  Lung rale sounds on auscultation            460 (69.8)                                                               220 (67.5)                                                                       240 (72.1)                                                             0.200
  Comorbid conditions                                                                                                                                                                                                                                                          
  Asthma                                      36 (5.5)                                                                 27 (8.3)                                                                         9 (2.7)                                                                0.002
  Heart failure                               51 (7.7)                                                                 35 (10.7)                                                                        16 (4.8)                                                               0.004
  Hematological disease                       63 (9.6)                                                                 32 (9.8)                                                                         31 (9.3)                                                               0.825
  Neuromuscular disease                       5 (0.8)                                                                  3 (0.9)                                                                          2 (0.6)                                                                0.683
  Autoimmune disease                          42 (6.4)                                                                 23 (7.1)                                                                         19 (5.7)                                                               0.478
  Immunosuppression                           138 (20.9)                                                               78 (23.9)                                                                        60 (18.0)                                                              0.062
  APACHE II score mean (SD)                   14.1 (4.3) [^b^](#jmv25502-tbl2-note-0003){ref-type="fn"}                14.5 (4.6) [^b^](#jmv25502-tbl2-note-0003){ref-type="fn"}                        13.9 (3.9) [^b^](#jmv25502-tbl2-note-0003){ref-type="fn"}              \<0.001
  Presenting clinical manifestations                                                                                                                                                                                                                                           
  Noninvasive mechanical ventilation          170 (25.8)                                                               92 (28.2)                                                                        78 (23.4)                                                              0.159
  Mechanical ventilation                      189 (28.7)                                                               103 (31.6)                                                                       86 (25.8)                                                              0.102
  Vasoactive drugs                            177 (26.9)                                                               89 (27.3)                                                                        88 (26.4)                                                              0.800
  Continuous venovenous hemofiltration        18 (2.7)                                                                 7 (2.1)                                                                          11 (3.3)                                                               0.363
  Corticoids                                  206 (31.3)                                                               119 (36.5)                                                                       87 (26.1)                                                              0.004

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; SALRTI, severe acute lower respiratory tract infection; SD, standard deviation.

Data is presented as no. (%) of patients unless otherwise indicated.

Values in brackets represent SD.
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3.2. Spectrum of respiratory viruses {#jmv25502-sec-0130}
------------------------------------

Overall, 326 (49.5%) samples were positive for at least one respiratory virus, and there were 36 (5.5%) cases of viral coinfections. The groups of viruses identified were as follows, in descending order of prevalence: IFV (n = 94, 14.3%), RSV (n = 75, 11.4%), HRV (n = 56, 8.5%), ADV (n = 55, 8.3%), PIV (n = 47, 7.1%), HCoV (n = 15, 2.3%), HMPV (n = 14, 2.1%), and HBoV (n = 11, 1.7%).

3.3. Impact of sex and age on virus detection {#jmv25502-sec-0140}
---------------------------------------------

The positive rates of viral infections in male and female patients were 48.44% (202 of 417) and 51.2% (124 of 242), respectively. No significant difference was found between both sexes (*χ* ^2^ = 0.480, *P* = 0.489). The positive rate in younger children (\< 5 years) was significantly higher than that in older children (\> 5 years) (52.5% vs 35.1%, *χ* ^2^ = 11.405, *P* = 0.001). Children aged 2 months to 1 year were the most susceptible to viral respiratory pathogens with a positive rate of 55.4% (Table [3](#jmv25502-tbl-0003){ref-type="table"}). However, the infection patterns of viruses were different among the age groups. RSV was highly clustered in patients with SALRTI who are younger than 3 years old (\> 10% positive rate). ADV accounted for 2.9% to 11.9% of the viruses identified in all age groups. This group of viruses was the common pathogen in all but with higher incidence in school‐aged children (5‐10 years old) in which IFV was the most frequent one (25.7%) (Table [3](#jmv25502-tbl-0003){ref-type="table"}).

###### 

Number of samples tested, positivity rates and viral findings by gender, season and age group

  Infections           Gender group (%) [^a^](#jmv25502-tbl3-note-0002){ref-type="fn"}   Age group (%) [^a^](#jmv25502-tbl3-note-0002){ref-type="fn"}   Seasonality (%) [^a^](#jmv25502-tbl3-note-0002){ref-type="fn"}                                                                                        
  -------------------- ----------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------- ----------- ----------- ----------- ----------- ------------ ----------- ----------- -----------
  Any viral etiology   202 (48.4)                                                        124 (51.2)                                                     133 (55.4)                                                       87 (54.4)   66 (45.5)   27 (38.6)   13 (29.5)   111 (54.7)   77 (49.0)   67 (43.5)   71 (49.0)
  ADV                  33 (7.9)                                                          22 (9.1)                                                       13 (5.4)                                                         19 (11.9)   16 (11.0)   2 (2.9)     5 (11.4)    20 (9.9)     13 (8.3)    12 (7.8)    10 (6.9)
  HMPV                 7 (1.7)                                                           7 (2.9)                                                        6 (2.5)                                                          7 (4.4)     1 (0.7)     0 (0)       0 (0)       12 (5.9)     2 (1.3)     0 (0)       0 (0)
  IFV                  57 (13.7)                                                         37(15.3)                                                       22 (9.1)                                                         25 (15.6)   26 (17.9)   18 (25.7)   3 (6.8)     35 (17.2)    14 (8.9)    7 (4.5)     38 (26.2)
  RSV                  45 (10.8)                                                         30 (12.4)                                                      54 (22.5)                                                        17 (10.6)   2 (1.4)     0 (0)       2 (4.5)     33 (16.3)    16 (10.2)   15 (9.7)    11 (7.6)
  HCoV                 11 (2.6)                                                          4 (1.7)                                                        7 (2.9)                                                          5 (3.1)     1 (0.7)     2 (2.9)     0 (0)       5 (2.5)      3 (1.9)     4 (2.6)     3 (2.1)
  HRV                  41 (9.8)                                                          15 (6.2)                                                       30 (12.5)                                                        12 (7.5)    8 (5.5)     3 (4.3)     3 (6.8)     10 (4.9)     16 (10.2)   21 (13.6)   9 (6.2)
  PIV                  29 (7.0)                                                          18 (7.4)                                                       20 (8.3)                                                         10 (6.3)    14 (9.7)    2 (2.9)     1 (2.3)     8 (3.9)      18 (11.5)   15 (9.7)    6 (4.1)
  HBoV                 9 (2.2)                                                           2 (0.8)                                                        5 (2.1)                                                          3 (1.9)     3 (2.1)     0 (0)       0 (0)       2 (1.0)      1 (0.6)     2 (1.3)     6 (4.1)
  Coinfections         26 (6.2)                                                          10 (4.1)                                                       19 (7.9)                                                         11 (6.9)    5 (3.4)     0 (0)       1 (2.3)     11 (5.4)     9 (5.7)     7 (4.5)     9 (6.2)
  Negative             215 (51.6)                                                        118 (48.8)                                                     107 (44.6)                                                       73 (45.6)   79 (54.5)   43 (61.4)   31 (70.5)   92 (45.3)    80 (51.0)   87 (56.5)   74 (51.0)

Abbreviations: ADV, adenovirus; HBoV, human bocavirus; HCoV, human coronavirus; HMPV, human metapneumovirus; HRV, human rhinovirus; IFV, influenza virus; PIV, parainfluenza virus; RSV, respiratory syncytial virus.

Data is presented as no. (%) of patients unless otherwise indicated.
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3.4. Seasonality {#jmv25502-sec-0150}
----------------

The patients were divided into four groups, in accordance with the seasons: (1) spring group (March, April, and May), 203 cases; (2) summer group (June, July, and August), 157 cases; (3) autumn group (September, October, and November), 154 cases; and (4) winter group (December, January, and February), 145 cases (Table [2](#jmv25502-tbl-0002){ref-type="table"}). In general, the total frequency of positive tests for viruses was slightly higher in spring than in autumn (*χ* ^2^ = 4.373, *P* = 0.037), but no significant difference was observed between summer and winter (*P* \> 0.05) (Table [3](#jmv25502-tbl-0003){ref-type="table"}). However, different viruses varied significantly in terms of the monthly cumulative results. IFV exhibited remarkable seasonal distributions. Peaks in IFV detection lasted from winter to early spring, with a positive rate of 51.4% (19 of 37) in January and 47.8% (11 of 23) in April. RSV and HMPV were more frequently detected in spring, PIV in summer, and HRV in autumn. ADV was detected almost throughout the year, peaking in April and October (Figure [1](#jmv25502-fig-0001){ref-type="fig"}).

![Monthly cumulative distribution of eight categories respiratory viral targets from 659 children with severe acute lower respiratory tract infection in Guangzhou from May 2015 to April 2018. Virus‐positive patient number of monthly cumulative results and the monthly detection rate (% of monthly detected cases) were shown. A, adenovirus (ADV); B, human metapneumovirus (HMPV); C, influenza virus (IFV); D, respiratory syncytial virus (RSV); E, human rhinovirus (HRV); F, parainfluenza virus (PIV); G, human coronavirus (HCoV); and H, human bocavirus (HBoV)](JMV-91-1633-g001){#jmv25502-fig-0001}

3.5. Clinical profiles associated with respiratory tract viral infection {#jmv25502-sec-0160}
------------------------------------------------------------------------

The most common symptoms associated with viral SALRTI were cough (95.1%), fever (≥ 38.0º = °C) (92.9%), difficulty breathing (71.8%), and sputum production (67.5%). Compared with negative cases, more patients were observed to have a runny nose, sputum, tachypnea, difficulty breathing, and wheezing (all *P* \< 0.05) (Table [2](#jmv25502-tbl-0002){ref-type="table"}). The clinical characteristics of patients with the four main respiratory viral infections are summarized in Table [4](#jmv25502-tbl-0004){ref-type="table"}. Among critically ill patients with IFV infection, fever (98.9%) was the most common symptom, but rales were not obvious compared with negative cases (55.3% vs 72.1%, *P* = 0.002). A significantly higher number of children had a runny nose (65.3%), difficulty breathing (66.7%), and increased rales (85.3%) in RSV infection than in IFV infection. More importantly, 25.3% of the children developed heart failure complications (all *P* \< 0.05). Runny nose and sore throat were more prevalent among HRV‐infected patients (67.9% and 25.0%, respectively) than among virus‐negative patients (18.9% and 5.4%, respectively). There were statistically significant differences in the prevalence of sputum production, tachypnea, difficulty breathing, wheezing, pulmonary rales, and radiographic evidence of pneumonia according to whether a patient was infected by ADV or negative (all *P* \< 0.05). Higher APACHE II scores were found in patients infected with RSV or ADV than in those infected with HRV, and more mechanical ventilation strategies were adopted in ADV‐infected cases (Table [4](#jmv25502-tbl-0004){ref-type="table"}).

###### 

Comparison of the clinical characteristics between four major viral infections in SALRTI

  Characteristics                             Negative (%)[^\*^](#jmv25502-tbl4-note-0003){ref-type="fn"}   IFV (%)[^\*^](#jmv25502-tbl4-note-0003){ref-type="fn"}   RSV (%)[^\*^](#jmv25502-tbl4-note-0003){ref-type="fn"}   HRV (%)[^\*^](#jmv25502-tbl4-note-0003){ref-type="fn"}   ADV (%)[^\*^](#jmv25502-tbl4-note-0003){ref-type="fn"}
  ------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Clinical history and physical examination                                                                                                                                                                                                                                            
  *T *≥ 38.0°C                                319 (95.8)                                                    93 (98.9)                                                65 (86.7)^a,b^                                           48 (85.7)^a,b^                                           54 (98.2)
  Cough                                       320 (96.1)                                                    88 (93.6)                                                72 (96.0)                                                51 (91.1)                                                54 (98.2)
  Runny nose                                  63 (18.9)                                                     12 (12.8)                                                49 (65.3)^a,b^                                           38 (67.9)^a,b^                                           6 (10.9)^c,d^
  Sore throat                                 18 (5.4)                                                      11 (11.7)                                                3 (4.0)                                                  14 (25.0)^a,c^                                           6 (10.9)
  Sputum production                           184 (55.3)                                                    54 (57.4)                                                41 (54.7)                                                32 (57.1)                                                40 (72.7)
  Tachypnea                                   104 (31.2)                                                    31 (33.0)                                                31 (41.3)                                                21 (37.5)                                                36 (65.5) ^a,b,d^
  Difficulty breathing                        177 (53.2)                                                    41 (43.6)                                                50 (66.7)^b^                                             28 (50.0)                                                42 (76.4) a,b,^d^
  Wheezing                                    59 (17.7)                                                     19 (20.2)                                                58 (77.3)^a,b^                                           27 (48.2)^a,b,c^                                         31 (56.4)^a,b^
  Radiographic evidence of pneumonia          255 (76.6)                                                    74 (78.7)                                                47 (62.7)                                                36 (64.3)                                                49 (89.1)^c,d^
  Lung rale sounds on auscultation            240 (72.1)                                                    52 (55.3)^a^                                             64 (85.3)^b^                                             38 (67.9)                                                29 (52.7)^a,c^
  Comorbid conditions                                                                                                                                                                                                                                                                  
  Asthma                                      9 (2.7)                                                       6 (6.4)                                                  8 (10.6)^a^                                              6 (10.7)^a^                                              4 (7.3)
  Heart failure                               16 (4.8)                                                      5 (5.3)                                                  19 (25.3)^a,b^                                           1 (1.8)^c^                                               6 (10.9)^c^
  Hematological disease                       31 (9.3)                                                      11 (11.7)                                                8 (10.7)                                                 9 (16.1)                                                 3 (5.5)
  Neuromuscular disease                       2 (0.6)                                                       1 (1.1)                                                  1 (1.3)                                                  0 (0)                                                    1 (1.8)
  Autoimmune disease                          19 (5.7)                                                      4 (4.3)                                                  6 (8.0)                                                  5 (8.9)                                                  3 (5.5)
  Immunosuppression                           60 (18.0)                                                     16 (17.0)                                                15 (20.0)                                                19 (33.9)                                                6 (10.9)^d^
  APACHE II score mean (SD)                   13.9 (3.9)                                                    14.8 (4.1)                                               15.2 (4.6)^a^                                            13.3 (3.7)^c^                                            15.3(5.0)^a,d^
  Presenting clinical manifestations                                                                                                                                                                                                                                                   
  Noninvasive mechanical ventilation          78 (23.4)                                                     26 (27.7)                                                32 (42.7)^a^                                             8 (14.3)^b,c^                                            15 (27.3)
  Mechanical ventilation                      86 (25.8)                                                     37 (39.4)                                                18 (24.0)                                                13 (23.2)                                                32 (58.2)^a,c,d^
  Vasoactive drugs                            88 (26.4)                                                     29 (30.9)                                                20 (26.7)                                                4 (7.1)                                                  21 (38.2)
  Continuous venovenous hemofiltration        11 (3.3)                                                      3 (3.2)                                                  0 (0)                                                    0 (0)                                                    3 (5.5)
  Corticoids                                  87 (26.1)                                                     29 (30.9)                                                43 (57.3)^a,b^                                           7 (12.5)^c^                                              18 (32.7)

*Note*: a: *P* \< 0.05 compared with Negative group; b: *P* \< 0.05 compared with IFV‐positive group; c: *P* \< 0.05 compared with RSV‐positive group; d: *P* \< 0.05 compared with HRV‐positive group.

Abbreviations: ADV, adenovirus; APACHE II, Acute Physiology and Chronic Health Evaluation II; HRV, human rhinovirus; IFV, influenza virus; RSV, respiratory syncytial virus; SALRTI, severe acute lower respiratory tract infection; SD, standard deviation.

Data is presented as no. (%) of patients unless otherwise indicated.
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4. DISCUSSION {#jmv25502-sec-0170}
=============

In this study, a thorough investigation of respiratory viruses was conducted in children with SALRTI who were admitted to the PICU in Guangzhou, China. The prevalence of eight categories of respiratory viruses and the clinical profiles of the four most common viral types (IFV, RSV, HRV, and ADV) were analyzed. Among the 659 samples, 326 (49.5%) contained at least one type of virus; this value was also observed in other studies conducted in patients admitted to the intensive care unit (ICU) in other areas (24.6%‐54.6%).[17](#jmv25502-bib-0017){ref-type="ref"}, [18](#jmv25502-bib-0018){ref-type="ref"}, [19](#jmv25502-bib-0019){ref-type="ref"} This suggests that the respiratory tract virus, a major cause of SALRTI resulting in global human morbidity and mortality, warrants national awareness for its detection and management.

Among the viruses detected in PICU patients with SALRTI, IFV was the most prevalent. Multiple reports have described the clinical features of IFV infection, and the spectrum of clinical presentation varies from self‐limiting respiratory tract illness to primary viral pneumonia that ultimately leads to respiratory failure, acute respiratory distress, multiorgan failure, and even death.[17](#jmv25502-bib-0017){ref-type="ref"}, [20](#jmv25502-bib-0020){ref-type="ref"} Interestingly, IFV viruses were found to exhibit remarkable seasonal distributions, with their peaks lasting from winter to early spring, which is similar to the findings in another report.[19](#jmv25502-bib-0019){ref-type="ref"} Most of the critically ill children were school aged. Moreover, 39.4% of the total infected patients required mechanical ventilation. These findings justified the need to maximize measures for preventing the spread of infection during epidemic periods and to implement active screening of influenza cases among the susceptible population.

In addition, RSV was identified to be the second prevalent virus type in children with SALRTI, consistent with the finding in other reports from developed and developing countries.[18](#jmv25502-bib-0018){ref-type="ref"}, [21](#jmv25502-bib-0021){ref-type="ref"} When children are hospitalized for RSV infection, they require inpatient resources at a very high rate. An investigation undertaken by a UK group demonstrated that RSV accounted for 15.6% of all admissions to intensive therapy units due to respiratory disease.[22](#jmv25502-bib-0022){ref-type="ref"} The findings of this study showed that RSV was the leading viral pathogen identified in infants less than 1 year of age who are admitted in the PICU for SALRTI with a higher APACHE II score than that of virus‐negative cases, suggesting that RSV could be associated with substantial morbidity and mortality. This study also demonstrated that RSV infection occurred throughout the year, exhibiting a clear seasonal trend. RSV infection peaked in March, later than that in other published reports showing that RSV infection occurred most frequently in temperate regions during the winter months.[23](#jmv25502-bib-0023){ref-type="ref"} This discrepancy may have resulted from the typical subtropical monsoon climate in Guangzhou, where March was considered an early beginning of spring.

In humans, HRV causes not only respiratory tract infection, including the most common cold but also severe respiratory illness such as pneumonia and bronchiolitis in children.[24](#jmv25502-bib-0024){ref-type="ref"} HRV was the third most frequently detected respiratory virus type in the present study. HRV isolates were detected each month of the year, and the highest positive rates were in September. This result was consistent with that of a previous study in Suzhou,[25](#jmv25502-bib-0025){ref-type="ref"} but different from that of a study in Changsha.[26](#jmv25502-bib-0026){ref-type="ref"} The possible explanation for this difference was that the predominant species of HRV varies from location to location and year to year. A few distinct clinical characteristics were observed when different groups of patients were compared. HRV infection was more common than virus‐negative cases with a runny nose, throat sore, and wheezing and more prevalent in children with concurrent asthma and immunosuppression. Similar data were reported in other studies, highlighting that HRV frequently exacerbates pre‐existing airway diseases such as asthma.[27](#jmv25502-bib-0027){ref-type="ref"} This may help inform clinicians of the strategies for the prevention and management of chronic diseases.

ADV was a significant cause of SALRTI, which continue to bring clinical challenges in terms of diagnostics and treatment.[28](#jmv25502-bib-0028){ref-type="ref"} During the study period, 8.3% (55 of 659) of patients with ADV infection were detected, consistent with the findings of a previous study showing that ADV accounts for 5% to 10% of acute respiratory tract infection in children.[29](#jmv25502-bib-0029){ref-type="ref"} It mostly affected children under the age of 5 (48 of 55), and the clinical features and disease progression in these cases are highly similar to those of acute respiratory distress syndrome caused by ADV in a previous report.[30](#jmv25502-bib-0030){ref-type="ref"} Nearly all patients presented with fever (98.3%) and cough (98.3%). However, compared with virus‐negative cases, more children presented with sputum production, tachypnea, difficulty breathing, and wheezing. A previous study showed that the respiratory rate was an independent risk marker for in‐hospital mortality in community‐acquired pneumonia (CAP) caused by ADV infection.[31](#jmv25502-bib-0031){ref-type="ref"} The APACHE II score, one of the most commonly used severity assessment tools for critically ill patients, also provides important prognostic information for ADV in SALRTI. The clinical course of admitted patients in this study showed a substantial proportion of severe illness with higher APACHE II scores in patients, requiring a greater number of therapeutic interventions such as mechanical ventilation (58.2%) during their ICU stay. Radiography could be helpful in the early diagnosis of ADV pneumonia even when lung rales were not evident on auscultation. Severe ADV pneumonia has been frequently described in immunocompromised patients.[28](#jmv25502-bib-0028){ref-type="ref"} Respiratory infection caused by ADV in immunocompetent patients was usually thought to be mild and self‐limited.[32](#jmv25502-bib-0032){ref-type="ref"} However, 89.1% (49 of 55) of ADV infection cases in this study were immunocompetent. With advancements in modern molecular techniques, ADV has been increasingly found to be involved in sporadic cases and outbreaks of severe CAP in healthy individuals,[33](#jmv25502-bib-0033){ref-type="ref"}, [34](#jmv25502-bib-0034){ref-type="ref"} thus warranting attention from clinicians.

Several limitations should be taken into account when interpreting the study results. First, this study was conducted at a single center, which might lead to the underestimation of the overall detection rate for the selected viruses. Second, despite testing for a large panel of respiratory viruses, bacterial infection was not evaluated due to the difficulty in obtaining adequate samples for culture. Nevertheless, the role of bacterial pathogens in the development of SALRTI symptoms was taken into consideration.[35](#jmv25502-bib-0035){ref-type="ref"} Further studies will thus be required to clarify their roles in SALRTI. Third, it should be considered that some respiratory viruses can be shed for long periods of time after infection or detection in asymptomatic children.[36](#jmv25502-bib-0036){ref-type="ref"} Hence, the investigation of respiratory specimens from asymptomatic children would make the role of these viruses in SALRTI clearer.

In summary, despite the aforementioned limitations, this 3‐year surveillance provides a basic profile of the spectrum, seasonality, age, and sex distribution as well as the clinical association of viral respiratory infections in the PICU at the medical center where the study was conducted. This profile would be useful in the examination of viruses as well as the development of novel strategies in managing viral infections in SALRTI.
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